MediMabBio
- Biotech or pharma, therapeutic R&D
MediMabBio is actively seeking strategic partnerships at BIO2025.
We offer multiple partnering opportunities across oncology, autoimmune diseases, and platform technologies:
- Immuno-oncology Assets
- MFA011: IL-15 immunocytokine fused to a differentiated anti-TIGIT antibody (available for licensing)
- MMB102: Anti-GITR agonist antibody (open to R&D collaboration and joint development)
- Autoimmune Disease Asset
- MFA031: TIGIT agonist fused with IL-10 cytokine (available for licensing)
- Platform Technologies
- Cytokine-Antibody Fusion Platform
- Artikine Platform: an AI-powered engineered cytokine platform
Visit our booth at the Korean Pavilion (#1664) for more information
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}